Home » News » AIM News » Evgen Pharma plc To hold Investor Symposium on the clinical significance of SFX-01
Evgen Pharma Plc

Evgen Pharma plc To hold Investor Symposium on the clinical significance of SFX-01

Evgen Pharma plc (LON:EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, have announced today that it is to hold an Investor Symposium for investors and analysts on the morning of Tuesday 18 September 2018.

The Investor Symposium, titled “The clinical significance of SFX-01”, will be an opportunity to engage with the Company and independent experts to help frame the significance of the two Phase II clinical read-outs of SFX-01 expected around the end of the year.

The morning will feature a short introduction by Evgen’s CEO, Stephen Franklin, followed by a series of presentations and a Q&A session. The presentations will include:

• Vadim Alexandre – Managing Director, Northland Capital Partners
The biotech investment market and Evgen Pharma plc

• Prof Albena Dinkova-Kostova – University of Dundee
The science behind sulforaphane

• Dr Sasha Howell – The Christie Hospital, Manchester
The STEM trial in breast cancer

• Sally Ross – Clinical Development Officer, Evgen
The SAS trial in haemorrhagic stroke and the preclinical pipeline

The event will be held at the offices of Buchanan, 107 Cheapside, London EC2V 6DN and will begin at 9.15am. The presentations will be available on the Evgen Pharma plc website on the day. No new material trading information will be disclosed.

Those interested in attending the event, can register with Buchanan on 020 7466 5000 or email tillya@buchanan.uk.com